Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

SBRT showed superiority over radiofrequency ablation in local progression-free survival and tumor control in small HCC but ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.

Typically, patients treated with systemic therapy for locally advanced hepatocellular carcinoma recur within ... 27.5 to 50 Gy in 5 fractions. The primary endpoint of this study was OS; secondary ...